QIAGEN Expands Alliance with Protedyne Corporation
Investment of approximately US$ 2.0 million
02-Feb-2005
In addition, QIAGEN will invest approximately US$ 2.0 million in Protedyne. QIAGEN has been granted exclusive access to Protedyne's high throughput automation platform technologies for filter-based nucleic acid sample preparation. This strategic alliance is the result of a successful collaboration announced in June 2004. The first commercial system will be available during Q2 of 2005.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.